Linical CoTSE:2183 +2.50%49 Gross Margin % is 1.37% as of Mar. 2026, which is 96% below its 10-year median of 31.78. GuruFocus rates TSE:2183 with a GF Score™ of 49/100 and a GF Value™ of 円310.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Linical Co ranks worse than 88.57% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Linical Co's Gross Profit for the
six
months ended in Mar. 2026 was 円52 Mil. Linical Co's Revenue for the
six
months ended in Mar. 2026 was 円3,806 Mil. Therefore, Linical Co's Gross Margin % for the quarter that ended in Mar. 2026 was 1.37%.
Warning Sign:
Linical Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -12.5%.
The historical rank and industry rank for Linical Co's Gross Margin % or its related term are showing as below:
TSE:2183'
s Gross Margin % Range Over the Past 10 Years
Min: 12.97 Med: 31.78 Max: 43.9
Current: 12.97
During the past 13 years, the highestGross Margin % of Linical Co was 43.90%. The lowest was 12.97%. And the median was 31.78%.
TSE:2183's Gross Margin % is ranked worse than 88.57% of 735
companies
in the Biotechnology industry
Industry Median: 60.9
vs TSE:2183: 12.97
Linical Co had a gross margin of 1.37% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Linical Co was -12.50% per year.
Linical Co (TSE:2183) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Linical Co had a gross margin of 1.37% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Linical Co Gross Margin % Related Terms
Linical Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Linical Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2183 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Linical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Linical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Linical Co (TSE:2183) has a Gross Margin % of 1.37% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Linical Co and its competitors. This is 96% below median its historical median of 31.78. Over the past decade, Linical Co's Gross Margin % has ranged from 12.97 to 43.90. According to the industry distribution chart, Linical Co ranks #651 out of 735 companies in the Biotechnology industry, placing it in the top 88.6%.
Is Linical Co's Gross Margin % too high?
Linical Co's current Gross Margin % of 1.37% is 96% below median its 10-year median of 31.78. Over the past 10 years, this metric has ranged from a low of 12.97 to a high of 43.90. The Biotechnology industry median Gross Margin % is 60.90. Linical Co's value of 1.37% is 97.8% below this industry median. Based on the distribution chart, Linical Co ranks #651 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Linical Co has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #651 out of 735 companies for Gross Margin %. This places Linical Co in the lower half of its industry. The industry median Gross Margin % is 60.90. Linical Co's value of 1.37% is 97.8% below this benchmark. Historically, Linical Co's own Gross Margin % has ranged from 12.97 to 43.90 over the past decade. While the company's 10-year median is 31.78 vs. the industry median of 60.90, Linical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Linical Co's current Gross Margin % of 1.37% is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current Gross Margin % is 1.37%, which is 96% below median its own 10-year median of 31.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円310.47, compared to a current price of 円205.00 — trading 34% below its estimated fair value. The current Gross Margin % is 1.37%, which is 96% below median its 10-year median of 31.78 and 97.8% below the Biotechnology industry median of 60.90. Linical Co's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Linical Co (TSE:2183), the current Gross Margin % is 1.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円205.00 is trading 34% below its estimated GF Value™ of 円310.47.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
Gross Margin %: 1.37% (96% below median its 10-year median of 31.78)
GF Value™: 円310.47 vs. price of 円205.00 (34% below fair value)
Industry Position: 97.8% below the Biotechnology median (#651 of 735)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
